Search

Here, we present a review on a fundamental radiochemical research topic performed by Swiss scientists in national and international collaborations, utilizing large accelerator facilities at the Paul Scherrer Institute as well as abroad. The chemical investigation of the heaviest elements of the periodic table is a truly multidisciplinary effort, which allows scientists to venture into a variety of fields ranging from nuclear and radiochemistry to experimental and theoretical work in inorganic and physical chemistry all the way to nuclear and atomic physics. The structure and fundamental ordering scheme of all elements in the periodic table, as established more than 150 years ago, is at stake: The ever increasing addition of new elements at the heavy end of the periodic table together with a growing influence of relativistic effects, raises the question of how much periodicity applies in this region of the table. Research on the heaviest chemical elements requires access to large heavy-ion accelerator facilities as well as to rare actinide isotopes as target materials. Thus, this scientific area is inevitably embedded in joint international efforts. Its fundamental character ensures academic relevance and thereby substantially contributes to the future of nuclear sciences in Switzerland.

Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Research. The facilities used for this purpose have evolved substantially over the last five decades. Many radiometals in use today, as radiopharmaceuticals, are for the diagnosis and treatment of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, developments at these facilities are lacking. Currently, the fixed 72 MeV proton beam at PSI is degraded at IP2 irradiation station to provide the desired energy to irradiate targets to produce the likes of 44Sc, 43Sc and 64Cu as a proof of principle, which are of great interest to the nuclear medicine community. This development work can then be implemented at facilities containing medical cyclotrons. A history of the development of radionuclides at PSI, along with current development and projects with partner institutions, is described.